BeiGene Drug Pipeline
29 active trials across 3 therapeutic areas
BeiGene maintains a substantial clinical development portfolio, with 31 active trials out of 135 total trials registered since 2008. The pipeline spans all phases of clinical development, with 16 active Phase 1 trials, 12 in Phase 2, 8 in Phase 3, and 1 in Phase 4. The company's research is heavily concentrated in oncology, which accounts for 47 active trials, representing 152% of active programs. Within oncology, the leading indications by active trial count are advanced solid tumors (7 active), non-Hodgkin lymphoma (6 active), non-small cell lung cancer (4 active), chronic lymphocytic leukemia (4 active), and bladder cancer (3 active). Outside of oncology, BeiGene has a smaller presence in immunology, with 2 active trials. No active trials are currently registered in infectious disease. The concentration of active trials in oncology, with several programs in Phase 3, suggests a strategic focus on near-term catalysts in this therapeutic area.
Oncology
BeiGene — Active Trials by Therapeutic Area
TheraRadar.com
Full Therapeutic Area Breakdown
2 more therapeutic areas: Immunology, Infectious Disease.
Active Trials by Phase
Top 10 Indications (active)
Total Trials by TA (lifetime)
Immunology
Infectious Disease
Click an indication to see the competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov · Trials registered 2008 onwards.